PCRC_EAZ171

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women.

This phase II trial studies how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. Drugs used in chemotherapy, such as docetaxel and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving docetaxel or paclitaxel may work better than other methods in reducing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Key Eligibility:
• Patients must be women with a known stage I-III invasive breast cancer diagnosis. Registration must occur within 84 days from the date of diagnosis.
• Patients must self-identify their race as black, African American, or of African descent; patients may be of any ethnicity.
• Patients must not have received prior taxane or prior/concurrent platinum therapy.
• Patients with a history of other cancers are eligible if they have not received prior taxane or platinum or vinca alkaloid therapy.
• Patients must not have pre-existing peripheral neuropathy.
Phase II
NCT04001829
Cancer
Breast
Alison Conlin, M.D.
ECOG-ACRIN
Amy Greathouse

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.